Additionally, miR-93-5p has been implicated in the regulation of carcinogenesis and tumor immunity by targeting the PD-L1/CCND1 axis, with potential use as a biomarker for patient risk stratification and treatment [41]. The gene discussed is CCND1; the disease is neoplasm.